Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Medco Weighing Opportunities For Consolidation In PBM Space – CEO Snow

  • News

Executive Summary

Acquiring an in-house pharmacy benefit manager from a health plan "could be the right thing for Medco" if done at the "right price," CEO David Snow commented during the firm's first quarter earnings call April 29

You may also be interested in...



Aetna PBM Spin-Off Floated As Insurer Uncertainties Over Health Reform Grow

News that Aetna is actively shopping around its internal pharmacy benefit management unit comes as insurers face growing uncertainty about how health care reform will impact their business

Aetna PBM Spin-Off Floated As Insurer Uncertainties Over Health Reform Grow

News that Aetna is actively shopping around its internal pharmacy benefit management unit comes as insurers face growing uncertainty about how health care reform will impact their business

Aetna PBM Spin-Off Floated As Insurer Uncertainties Over Health Reform Grow

The three biggest standalone PBMs are considered likeliest suitors if a sale occurs.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

FDA’s Califf Calls For Return To Large, Simple Trials Without The ‘Useless Stuff’ That Slows Development

‘Stop Fighting Us’ On Inspections, US FDA’s Califf Tells Industry; Foods Modernization Will Bring ‘Big Change’ To Drug Quality Systems

US FDA Program Streamlining COVID-19 Treatment Development Still Working As Emergency Ends

Biogen/Ionis’ Tofersen: US FDA Considering Both Accelerated And Regular Approval In ALS

See All
UsernamePublicRestriction

Register

PS051013

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By